These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20877297)

  • 1. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response.
    Ji Y; Biernacka J; Snyder K; Drews M; Pelleymounter LL; Colby C; Wang L; Mrazek DA; Weinshilboum RM
    Pharmacogenomics J; 2012 Feb; 12(1):78-85. PubMed ID: 20877297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder.
    Illi A; Setälä-Soikkeli E; Kampman O; Viikki M; Nuolivirta T; Poutanen O; Huhtala H; Mononen N; Lehtimäki T; Leinonen E
    Psychiatry Res; 2010 Mar; 176(1):85-7. PubMed ID: 20071037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.
    Kocabas NA; Faghel C; Barreto M; Kasper S; Linotte S; Mendlewicz J; Noro M; Oswald P; Souery D; Zohar J; Massat I
    Int Clin Psychopharmacol; 2010 Jul; 25(4):218-27. PubMed ID: 20531207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.
    Ellsworth KA; Moon I; Eckloff BW; Fridley BL; Jenkins GD; Batzler A; Biernacka JM; Abo R; Brisbin A; Ji Y; Hebbring S; Wieben ED; Mrazek DA; Weinshilboum RM; Wang L
    Pharmacogenet Genomics; 2013 Mar; 23(3):156-66. PubMed ID: 23324805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD).
    Kocabas NA
    CNS Neurol Disord Drug Targets; 2012 May; 11(3):264-72. PubMed ID: 22483292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder.
    Perlis RH; Fijal B; Adams DH; Sutton VK; Trivedi MH; Houston JP
    Biol Psychiatry; 2009 May; 65(9):785-91. PubMed ID: 19095219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.
    Ji Y; Hebbring S; Zhu H; Jenkins GD; Biernacka J; Snyder K; Drews M; Fiehn O; Zeng Z; Schaid D; Mrazek DA; Kaddurah-Daouk R; Weinshilboum RM
    Clin Pharmacol Ther; 2011 Jan; 89(1):97-104. PubMed ID: 21107318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SLC6A4 variation and citalopram response.
    Mrazek DA; Rush AJ; Biernacka JM; O'Kane DJ; Cunningham JM; Wieben ED; Schaid DJ; Drews MS; Courson VL; Snyder KA; Black JL; Weinshilboum RM
    Am J Med Genet B Neuropsychiatr Genet; 2009 Apr; 150B(3):341-51. PubMed ID: 18618621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.
    Gupta M; Neavin D; Liu D; Biernacka J; Hall-Flavin D; Bobo WV; Frye MA; Skime M; Jenkins GD; Batzler A; Kalari K; Matson W; Bhasin SS; Zhu H; Mushiroda T; Nakamura Y; Kubo M; Wang L; Kaddurah-Daouk R; Weinshilboum RM
    Mol Psychiatry; 2016 Dec; 21(12):1717-1725. PubMed ID: 26903268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.
    Athreya AP; Neavin D; Carrillo-Roa T; Skime M; Biernacka J; Frye MA; Rush AJ; Wang L; Binder EB; Iyer RK; Weinshilboum RM; Bobo WV
    Clin Pharmacol Ther; 2019 Oct; 106(4):855-865. PubMed ID: 31012492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients.
    Tsai SJ; Gau YT; Hong CJ; Liou YJ; Yu YW; Chen TJ
    J Affect Disord; 2009 Feb; 113(1-2):183-7. PubMed ID: 18533273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.
    Qin S; Eugene AR; Liu D; Zhang L; Neavin D; Biernacka JM; Yu J; Weinshilboum RM; Wang L
    Clin Pharmacol Ther; 2020 Mar; 107(3):662-670. PubMed ID: 31628858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catechol O-methyltransferase pharmacogenomics: human liver genotype-phenotype correlation and proximal promoter studies.
    Zhang J; Ji Y; Moon I; Pelleymounter LL; Ezequel Salavaggione O; Wu Y; Jenkins GD; Batzler AJ; Schaid DJ; Weinshilboum RM
    Pharmacogenet Genomics; 2009 Aug; 19(8):577-87. PubMed ID: 19641441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.
    Biernacka JM; Sangkuhl K; Jenkins G; Whaley RM; Barman P; Batzler A; Altman RB; Arolt V; Brockmöller J; Chen CH; Domschke K; Hall-Flavin DK; Hong CJ; Illi A; Ji Y; Kampman O; Kinoshita T; Leinonen E; Liou YJ; Mushiroda T; Nonen S; Skime MK; Wang L; Baune BT; Kato M; Liu YL; Praphanphoj V; Stingl JC; Tsai SJ; Kubo M; Klein TE; Weinshilboum R
    Transl Psychiatry; 2015 Apr; 5(4):e553. PubMed ID: 25897834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter variation in the catechol-O-methyltransferase gene is associated with remission of symptoms during fluvoxamine treatment for major depression.
    Fukui N; Suzuki Y; Sugai T; Watanabe J; Ono S; Tsuneyama N; Someya T
    Psychiatry Res; 2014 Aug; 218(3):353-5. PubMed ID: 24814141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin.
    Arias B; Serretti A; Lorenzi C; Gastó C; Catalán R; Fañanás L
    J Affect Disord; 2006 Feb; 90(2-3):251-6. PubMed ID: 16356553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample.
    Kraft JB; Peters EJ; Slager SL; Jenkins GD; Reinalda MS; McGrath PJ; Hamilton SP
    Biol Psychiatry; 2007 Mar; 61(6):734-42. PubMed ID: 17123473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics.
    Ji Y; Biernacka JM; Hebbring S; Chai Y; Jenkins GD; Batzler A; Snyder KA; Drews MS; Desta Z; Flockhart D; Mushiroda T; Kubo M; Nakamura Y; Kamatani N; Schaid D; Weinshilboum RM; Mrazek DA
    Pharmacogenomics J; 2013 Oct; 13(5):456-63. PubMed ID: 22907730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics studies in STAR*D: strengths, limitations, and results.
    Laje G; Perlis RH; Rush AJ; McMahon FJ
    Psychiatr Serv; 2009 Nov; 60(11):1446-57. PubMed ID: 19880459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms.
    Gudayol-Ferré E; Herrera-Guzmán I; Camarena B; Cortés-Penagos C; Herrera-Abarca JE; Martínez-Medina P; Asbun-Bojalil J; Lira-Islas Y; Reyes-Ponce C; Guàrdia-Olmos J
    Hum Psychopharmacol; 2012 Nov; 27(6):577-86. PubMed ID: 24446536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.